CIP
KYNB

Chartwell Investment Partners’s Kyntra Bio KYNB Stock Holding History

Chartwell Investment Partners’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-704
Closed -$650K – 421
2019
Q3 		$650K Hold
704
– – 0.02% 384
2019
Q2 		$795K Sell
704
-1,059
-60% -$1.16M 0.03% 386
2019
Q1 		$2.4M Buy
1,763
+24
+1% +$32.5K 0.08% 307
2018
Q4 		$2.01M Buy
1,739
+423
+32% +$475K 0.07% 333
2018
Q3 		$2M Buy
+1,316
New +$2.03M 0.06% 385

Other funds holding KYNB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Chartwell Investment Partners's KYNB Position: Q4 2019 in Review

Chartwell Investment Partners sold out of Kyntra Bio (KYNB) in Q4 2019, closing a stake of 704 shares — an estimated $650K sold.

Chartwell Investment Partners first reported a position in KYNB in Q3 2018 and held it in 5 quarters. The position peaked at $2.4M in Q1 2019. 213 funds tracked by Wall St. Rank hold KYNB as of Q4 2019.

  • Chartwell Investment Partners reported no remaining Kyntra Bio position as of Q4 2019 after selling out during the quarter.
  • Chartwell Investment Partners sold 704 Kyntra Bio shares in Q4 2019, an estimated $650K.
  • Chartwell Investment Partners first reported a position in Kyntra Bio in Q3 2018 and held it in 5 quarters.
  • Chartwell Investment Partners's Kyntra Bio position peaked at $2.4M in Q1 2019.
  • 213 funds tracked by Wall St. Rank held Kyntra Bio as of Q4 2019.

Based on Chartwell Investment Partners's 13F filing for Q4 2019, filed 29 Jan 2020.